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Abstract
Background: Lymphatic filariasis (LF) is a mosquito-borne parasitic disease which is targeted for elimination as a
public health problem worldwide. Niue is a small self-governing South Pacific island nation with approximately
1600 residents that was formerly LF endemic. Here, we review the progress made towards eliminating LF in Niue
since 1999.
Methods: This study has reviewed all the available literature relating to LF in Niue to assess surveillance efforts and the
elimination of transmission. Reviewed documentation included both published and unpublished works including
historical reports of LF, WHO PacELF records, and Niue Country Reports of the national LF elimination program.
Findings: Niue conducted mapping of baseline LF endemicity by testing the total present and consenting population
for LF antigen with immunochromatographic test (ICT) in 1999, when circulating filarial antigen prevalence was
3.1% (n = 1794). Five nationwide annual mass drug administration (MDA) rounds with albendazole (400mg) and
diethylcarbamazine citrate (DEC) were undertaken from 2000 to 2004, with coverage reported from distribution records
ranging from 78 to 99% of the eligible population, which excluded pregnant women and children under 2 years of
age. A further whole population survey using ICT in 2001 found 1.3% positive (n = 1630). In 2004, antigen prevalence
had reduced to 0.2% (n = 1285). A similar post-MDA survey in 2009 indicated antigen prevalence to be 0.5% (n = 1378).
Seven positive cases were re-tested and re-treated every six months until negative.
Conclusions: After five rounds of MDA, Niue had reduced the LF antigen population prevalence in all ages from 3.1%
to below 1% and maintained this prevalence for a further five years. Due to Niue’s small population, surveillance was
done by whole population surveys. Niue’s results support the WHO recommended strategy that five to six rounds of
annual MDA with effective population coverage can successfully interrupt the transmission of LF. Niue received official
acknowledgement of the validation of elimination of LF as a public health problem by the WHO Director-General and
WHO Western Pacific Regional Office (WPRO) Regional Director at the 67th session of the Regional Committee for the
Western Pacific held in Manila in October 2016.
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Background
Lymphatic filariasis (LF) is a mosquito-borne parasitic
disease. Worldwide, the disease is caused by three spe-
cies of parasitic worm, namely Wuchereria bancrofti,
Brugia malayi, and Brugia timori [1]. The parasites are
transmitted to humans via mosquitoes from the Anoph-
eles, Aedes, Culex, and Mansonia genera [2]. In the
South Pacific, W. bancrofti is the parasite responsible for
LF [1]. Parasites enter the body after a blood meal and
settle in the lymphatic system where they mature, mate,
and release millions of microfilariae into the blood-
stream. Early stages of infection are frequently asymp-
tomatic [1], although intermittent episodes of acute
dermatolymphangioadenitis and acute filarial lymphan-
gitis occur [3, 4]. If untreated infection persists, second-
ary bacterial infections and inflammation occur, and
damage caused to the lymphatic system accumulates,
resulting in some individuals in severely disabling and
disfiguring manifestations of lymphoedema, elephantia-
sis, and hydrocele [1, 4]. Globally, LF is the second lead-
ing cause of chronic disability [5]. The disease imposes
considerable economic and psychosocial hardship on
sufferers, their carers, and families [6–8].
In 1997, the Member States of the WHO at the World
Health Assembly (WHA) committed to eliminating LF
as a public health problem internationally through Reso-
lution WHA50.29 [9]. As a result, the World Health
Organization (WHO) launched the Global Programme
to Eliminate Lymphatic Filariasis (GPELF), with the aim
of eliminating LF by the year 2020 [5]. The strategy in-
cluded interrupting the transmission of LF through mass
drug administration (MDA) and alleviating current suf-
fering through improved morbidity management and
disability prevention (MMDP) [5, 10, 11]. In 1999, under
the auspices of the WHO, the regional arm of GPELF,
the Pacific Programme to Eliminate Lymphatic Filariasis
(PacELF), commenced in 22 Pacific Island Countries and
Territories (PICTs) [1, 12, 13] and included endemic
island nations such as Niue.
Niue (NEW-ay) is a self-governing South Pacific Ocean
island. The elevated coral atoll is located approximately
660 km southeast of Samoa, 480 km east of Tonga, and
2400 km northeast of New Zealand (19° S 169° W) [14].
The island covers approximately 261.46 km2 and is
divided into 14 administrative areas, with the capital,
Alofi, divided into two districts: Alofi South and Alofi
North (Fig. 1).
Niue’s population has been in decline for many de-
cades. In 1971, Niue’s population was 4990. Twenty-six
years later in 1997, however, the population had fallen to
2088 residents [14]. Emigration loss to neighboring New
Zealand (NZ) has been cited as a contributing factor to
population decline [15]. Figures suggest roughly 90% of
Niue’s population live and work in NZ where they
concurrently hold automatic citizenship [14]. NZ census
data (1996) indicated approximately 18,477 Niueans re-
sided in NZ [16]. More recent estimates suggest Niue’s
population is roughly 1611 (2011), with population di-
versity broken down into Niuean (66.5%), part-Niuean
(13.4%) (Tongan, Tuvaluan, Samoan), and non-Niuean
(20.1%) (Asian and European) [1, 14]. Niue residents
enjoy a relatively high standard of living. All people have
universal access to free education and healthcare; hous-
ing and hygiene are all of relatively high standard [17].
Niue’s climate is tropical. Average daily temperatures
range from 24 to 27 °C [14]. The wet season from
November to April brings high humidity, rainfall, and
warm temperatures which are favorable conditions for
mosquito breeding [14]. The primary mosquito vector
responsible for transmitting LF throughout Polynesia is
the genus Aedes (Ae.) [18]. In Niue, the specific species
responsible for transmitting LF is Ae. cooki [1]. Ae. cooki
bites during the day, dusk, and dawn and commonly
breeds in stagnant water containers such as cisterns and
coconut shells [15].
Monitoring and surveillance frameworks: GPELF and
PacELF guidelines
The Global Programme to Eliminate Lymphatic Filariasis
(GPELF) recommended that elimination efforts occur in
programmatic stages. These included mapping, MDA,
sentinel site surveillance during MDA, “stop MDA deci-
sion” surveys, post-MDA surveillance, and verification
[11]. Mapping required countries to survey and map LF
to determine whether Mf or antigenemia (Ag) preva-
lence was > 1%, in which case countries were considered
endemic [11]. Endemic countries required annual MDAs
be undertaken for at least five rounds, consisting of
combined albendazole (400 mg) plus diethylcarbamazine
citrate (DEC) (6 mg/kg) or (in countries where oncho-
cerciasis is co-endemic) ivermectin (150–200 μg/kg)
[6, 11]. Sentinel sites (villages surveyed longitudinally)
and spot check village surveys were done during MDA
and prior to larger surveys to decide whether MDA could
be stopped. After MDA was stopped, post-MDA surveil-
lance was required to monitor infection levels for approxi-
mately five years.
The initial recommendations for stopping MDA sur-
veys were for lot quality assurance sampling (LQAS) sur-
veys in 3000 children aged five years, to determine
whether transmission was still occurring, with an elimin-
ation criterion of < 0.1% circulating filariasis antigen
(CFA) prevalence [1, 19]. The rationale for surveying
children was that if adequate MDA coverage (> 65% of
the eligible population) had decreased population infec-
tion rates, this would prevent transmission and thus in-
fection in young children who were born after the
commencement of the MDA [20]. However, the PacELF
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program did not feel confident in using only young chil-
dren for the stop MDA decision, especially in small
countries with few children. Therefore, a survey of all
age groups through community cluster sampling (known
as the PacELF C-survey) was used to decide whether to
stop MDA [1].
Revised GPELF guidelines in 2011 modified the LQAS
method, and the cutoffs for “passing” a transmission
assessment survey (TAS) to < 1% CFA prevalence in
five-to-six-year-olds (in Aedes transmission areas) [11,
20]. The TAS was recommended by GPELF to be used
for both the stop MDA decision and for post-MDA sur-
veillance of at least two more TAS surveys at
two-to-three-year intervals [6]. This is in contrast to earl-
ier PacELF guidelines mentioned above, in which the rec-
ommendation was to survey all ages for the stop MDA
decision and ensure antigen prevalence in all ages was <
1%. Under PacELF, once MDA was stopped, surveys in
children only would then be done, as for TAS.
For validation of elimination (assuming all TAS were
passed and sufficient time elapsed since MDA), coun-
tries then develop a dossier detailing national epidemio-
logical data and evidence of the absence of transmission
of LF to support their claim. This dossier is reviewed by
an independent Dossier Review Group and the WHO
Regional Programme Review Group. If successful, the
country receives an official acknowledgement by the
WHO as having successfully eliminated LF as a public
health problem [6]. This elimination process is illus-
trated in Fig. 2.
Unlike many GPELF countries, the smaller population
sizes of many PICTs made the initial LQAS low-level
elimination target (0.1%) difficult. In response, the
WHO Western Pacific Regional Office (WPRO) pro-
gram (PacELF) developed its own monitoring and evalu-
ation framework. In 2003 and 2004, PacELF guidelines
used a community cluster survey in all ages for the deci-
sion to stop MDA, with an elimination target of antigen
Fig. 1 Niue and 14 districts (villages). Source [28]
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prevalence < 1% where W. bancrofti was endemic and
Aedes the principal vector [11].
Niue was a special case within PacELF. The program
spanned the time period of both PacELF and GPELF
guidelines, but in fact, due to Niue’s small population
size, the program conducted only whole population
surveys rather than sentinel sites, village cluster surveys,
or TAS/child transmission surveys at all program
decision points.
History of LF in Niue prior to PacELF
Suspect cases of LF existed in the Pacific Islands as early
as in 1785 when Captain James Cook noted symptoms
in Tongans that closely resembled elephantiasis [1]. In
1954, a microfilariae (Mf) survey was undertaken in
Niue to assess the number of positive carriers, revealing
a prevalence of 22.2% (166/748) [17, 21]. Three MDAs
were undertaken before the commencement of PacELF.
The first MDA was in 1956, the second in 1972, and the
third in 1997 [1]. There were four large blood surveys
conducted between 1956 and 1996, although the
sampling methodology used and age groups tested are
not clear.
The initial MDA in January of 1956 consisted of DEC
50mg administered monthly [17]. Reports of pain in the
joints and limbs were noted in asymptomatic positive
carriers 24 h following MDA [17]. A follow-up survey
conducted in December of 1956 on the population aged
six years and older showed Mf prevalence had reduced
to 3.0% (83/2791) [17]. Positive individuals were treated
intensively with DEC 50mg three times daily for two
weeks with a week interval between another week of
treatment, continuing until individuals tested Mf nega-
tive. Four years later, in 1960, another Mf survey re-
vealed population prevalence had risen slightly to 3.2%
(31/957) [22].
Sixteen years after the first 1956 MDA and twelve years
after the 1960 survey, a Mf survey in 1972 of almost the
whole population (99.7%) revealed that prevalence had
risen to 16.4% (724/4408) [23]. Subsequently, in 1972, a
second MDA was carried out with DEC (6 mg/kg once
weekly for twelve weeks, followed by once monthly for
twelve months) [23]. Coverage was reported as 98.4% al-
though the denominator used (total or eligible popula-
tion) was not clear, nor whether this was for the entire
population or a sample of the entire population. How-
ever, only 56.6% of the targeted population completed
the full course of MDA and no follow-up surveys were
undertaken [15].
In 1996, a survey on 82% of the population revealed a
Mf prevalence of 1.8% (26/1471) [24]. In 1997, a third
whole-population MDA was undertaken (on those 4
years or older) with combined DEC (6 mg/kg) and iver-
mectin (200 μg/kg), with a reported coverage of 87%
[15]. These surveillance and control activities are dis-
played in Fig. 3.
Methods
During October of 2017, we collected and reviewed both
unpublished and published WHO and PacELF program
Fig. 2 The Global Programme to Eliminate Lymphatic Filariasis (GPELF) Strategy. Arrows represent epidemiological assessment recommended
as part of monitoring and evaluation of the national program. VC/IVM, vector control and integrated vector management; MDA, mass drug
administration; TAS, transmission assessment survey; M&E, monitoring and evaluation; MMDP, morbidity management and disability prevention.
Source [20]
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data relating to Niue. We also searched for associated
literature regarding LF elimination and surveillance and
control activities in Niue. Types of literature retrieved
included PacELF data books including MDA data and
blood survey results, program guidelines, unpublished
data, and country reports. Other papers we reviewed
were historical filariasis reports relating to Niue and more
recently published peer-reviewed literature. Where litera-
ture was not accessed through the WHO Collaborating
Centre PacELF data warehouse held at James Cook
University, it was available freely online. We have
reviewed this literature and extracted key data to write
and inform this review.
Findings
PacELF was launched in 1999. In September of the same
year, an initial baseline survey of LF antigenemia
prevalence was undertaken on Niue’s whole population
(aged two years and older). Niue’s population antigen
prevalence was 3.1% [22] and, therefore, required five
rounds of MDA. All antigen prevalence testing was
undertaken using a standardized immunochromato-
graphic rapid card test (ICT) which has high sensitivity
(96–100%) and specificity (95–100%) [8].
Prior to the first MDA, a national awareness campaign
was undertaken, including a television awareness pro-
gram, a radio announcement, and a national distribution
of filariasis leaflets [15]. In 2000, the first national MDA
round was undertaken using a combined regimen of
DEC (6 mg/kg) and albendazole (400 mg). The main
distribution method was people coming to the village
community halls to obtain medicines from trained dis-
tributors who insisted upon directly observed therapy
(DOT) [15]. Absentees had to come and pick their medi-
cines at the hospital or it was delivered to their homes
following the MDA. The second nationwide MDA round
was undertaken in March of 2001 using the aforemen-
tioned drug regimen. In September of the same year, a
whole-population survey was undertaken by ICT. In
March of 2002 and 2003, third and fourth national
MDA rounds were undertaken (using the aforemen-
tioned drug regimen), and in addition, the previously
positive cases were followed up and treated if necessary.
In July of 2004, a fifth and final MDA round was under-
taken and was followed up by a national stop MDA
C-survey in August. Five years after the last MDA
round, in 2009, a whole-population survey was again
undertaken. Those who tested positive were re-tested
and re-treated every six months until the results became
negative. In total, five annual rounds of MDA were com-
pleted. A timeline showing these programmatic and
surveillance activities is given in Table 1.
In 1999, Niue’s baseline survey revealed an antigene-
mia prevalence of 3.1% (56/1794) M = 42, F = 14 [22].
High numbers of positive cases were seen in Hikutavake
(n = 13) and Tamakautonga (n = 13) villages, located
north and southwest of the island, respectively [22].
These are coastal villages (Fig. 1) with adjacent rural
areas that can harbor mosquitoes, unlike other
villages on the island from Vaiea to Mutulau. No
children (< ten years old) at baseline tested positive
(n = 280); however, there were seven positives in the
Fig. 3 LF monitoring and surveillance history prior to PacELF in Niue (1950–1998). Y-axis, percentage %; X-axis, year
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10–19 years age group (n = 453). Prevalence was highest
in those aged 20–29, 50–59, or 60+ years with consistently
more positive results recorded for males than females
(Fig. 4).
After MDA2 in 2001, a whole population survey showed
antigenemia prevalence had fallen to 1.3% (22/1630)
with positive cases seen in, amongst other locations,
Tamakautonga village (n = 4) and Alofi North (n = 4)
[22]. In 2002, a follow-up survey of positive cases that
had been identified in previous surveys (n = 20) re-
vealed 12 tested ICT positive. A further follow-up
survey in 2003 of positive cases (n = 26) revealed 16
tested ICT positive [22]. All cases were treated.
After MDA5 in 2004, a whole-population stop MDA
survey revealed antigenemia prevalence to be 0.2% (3/
1285) [18]. No further MDA was given after 2004. A
whole-population survey in 2009 found an overall anti-
genemia prevalence of 0.51% (n = 1378) and no positive
Table 1 Program timeline and surveillance activities in Niue, 1999–2017
Year Activity Detail and location of activity
1999 Baseline survey Whole population mapping baseline survey (by ICT)
Nationwide education and awareness campaign
2000 MDA1 Nationwide MDA (combined DEC and albendazole)
2001 MDA2 Nationwide MDA (combined DEC and albendazole)
Mid-term survey Mid-term whole population survey (ICT)
2002 MDA3 Nationwide MDA (combined DEC and albendazole)
Follow-up Testing (by ICT) of positive cases and treatment
2003 MDA4 Nationwide MDA (combined DEC and albendazole)
Follow-up Testing (by ICT) of positive cases and treatment
2004 MDA5 Final Nationwide MDA (combined DEC and albendazole)
Stop MDA survey Nationwide Survey by ICT in all ages
2006 Follow-up Follow-up of one +ve case undertaken
2009 Post MDA survey Nationwide Post-MDA survey (by ICT all ages)
Follow-up +ve cases re-tested, re-treated every six months until negative
2012 Dossier development Dossier for the validation of elimination of LF prepared
2013 Dossier submission Validation dossier submitted to WHO Review Group
2016 Elimination validation Official acknowledgement received from WHO of the validation of elimination of LF as a public health problem
Fig. 4 Percentage of positive cases (ICT) by age and gender, Niue 1999. Y-axis, percentage positive (95% confidence interval); X-axis, age group.
Source: Adapted from [22]. Error bars represent binomial 95% confidence intervals
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cases in six to seven year-old children. The seven indi-
viduals who tested positive in 2009 were re-tested with
blood ICT tests and treated (if positive) every six months
until testing negative (Table 2).
The minimum coverage for annual MDA to be consid-
ered effective was ≥ 65% of the total population [20].
Niue reported high rates of effective coverage based on
the census population denominator (Fig. 5). The average
MDA coverage across the five MDA rounds was 87.7%
(Fig. 5).
Only a small proportion of the population did not par-
ticipate in MDA. The principal reason reported for not
participating in MDA was absence at the time of drug
distribution. Absenteeism was the primary reason given
for non-treatment in MDA2 (73% of 142 reasons of any
type), MDA3 (66% of 105 reasons of any type), and
MDA4 (63% of 126 reasons of any type). The main
reason for absence was residents who had migrated to NZ
and students studying overseas. Some new residents or ex-
patriates did not participate if they were not fully aware of
the program. In the second MDA, the highest reported ab-
sences were recorded in Lakepa (n = 30), followed by Alofi
North (n = 23). In the third MDA, the highest recorded ab-
sences were in Alofi South (n = 30) followed by Alofi North
(n = 19). In the fourth MDA, the highest reported absence
was seen in Tuapa (n = 39) followed by Alofi North (n =
12) [22]. Aside from absenteeism, other reported reasons
for not engaging in MDA were pregnancy, infancy, or a
small number due to extreme age [22]. There were no for-
mal reports of adverse drug reactions (ADRs) from MDA,
but informal complaints of fatigue and sore body were
noted. This data could be included amongst reasons for
missing MDA listed in data books as “Other”, although this
remains undistinguishable [22].
MMDP: LF morbidity in Niue
For every person with lymphoedema, elephantiasis, or
hydrocele, a minimum package of care for management of
morbidity and prevention of disability (MMDP) must be
made available (Fig. 2) [20, 25]. This care must include
MDA or individual treatment to destroy remaining adult
parasites and microfilaria, surgery for hydrocele in W. ban-
crofti endemic areas, treatment for episodes of adenolym-
phangitis (ADL), and management of lymphoedema [6,
25]. In 2012, it was reported that there had been no known
cases of elephantiasis or filarial hydrocele in Niue for more
than a decade and that the last person suffering from ele-
phantiasis died twelve years ago [15]. Since then, there
Table 2 Results of filarial blood surveys in Niue under PacELF
Year Sample ICT examined (n) ICT positive (n) ICT positive (%)
1999 Whole population 1794 56 3.1
2001 Whole population 1630 22 1.3
2002 Follow-up of + ve cases 20 12 60.0
2003 Follow-up of + ve cases 26 16 61.5
2004 Whole population 1285 3 0.2
2006 Follow-up + ve cases 1 0 0.0
2009 Whole population 1378 7 0.5
Source: Adapted from [22, 27]
Fig. 5 Annual MDA coverage under PacELF Niue 2000–2004. Y-axis, percent (%) treated. Source: Adapted from [22, 27]
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have been no reports of filarial hydrocele or acute filariasis
[15].
Discussion
Several factors have supported the LF elimination suc-
cess seen in Niue. Firstly, Niue had a small, easily-ac-
cessible resident population, good leadership, and
committed Health Department staff as well as good
communication with the villages' councils, meaning ef-
fective coverage rates were possible throughout the pro-
gram (> 65%). Niue also had a low initial baseline
antigen prevalence of 3.1% (by ICT) [18]. The national
LF elimination program in Niue also actively pursued in-
dividuals who were absent at the time of each MDA to
ensure future treatment (e.g., residents returning from
overseas who were prompted to collect their tablets).
This also contributed to Niue being the only PacELF
program to undertake whole-population surveys with re-
liable cross-sectional data, rather than undertaking
stratified cluster surveys or child transmission surveys
like other LF programs [18].
There are some limitations to this study. Information
on LF prior to 1999 does not report the sampling
method used to test individuals or the population de-
nominator for studies. The population of Niue fluctuates
widely, with a large proportion of the population travel-
ing temporarily or permanently to NZ. The population
has dropped from around 5000 in the 1960s to less than
2000 today. The number tested in surveys during
PacELF represents an unknown (although large) propor-
tion of the resident population. It is not clear why there
was an increase in the number of positive and examined
cases in 2003, compared with the previous 2002
follow-up survey.
A factor that may have supported success for the LF
program was that, prior to the MDA period with the
PacELF program, Niue had a de-worming program tar-
geting school-aged children for over ten years. This may
have contributed to the finding that no children with
positive ICT were found pre- or post-MDA. As there is
only one primary school in Niue, it was easy for a nurse
to monitor and ensure children completed treatment.
There was a stool survey undertaken by WHO in 2002
in which no helminths were found in local children,
except one which was an imported case.
During the pre-MDA period, there was limited move-
ment of people in and out of Niue, as there was only
one flight to and from the island each week. The num-
ber of absentees tended to increase when more students
left the island for studies overseas, and some residents
left for medical treatment in Auckland after which they
needed clearance to return to the island. The number of
immigrants during the pre-MDA period was also re-
stricted due to a government immigration policy: a
health clearance was required before an entry permit
was granted only for those who wanted to set up per-
manent residence on the island. During the MDA pro-
gram (which was also occurring in other Pacific
countries and territories), permanent residents from en-
demic countries such as Tonga, Samoa, or Tuvalu who
wished to migrate to Niue but were not tested or treated
in their home country were offered ICT. However, no
positives were found. From 2012, as part of immigration
requirements, any external applicants seeking residency
(from another Pacific island) had to undergo an LF ICT
test and, if found positive, were offered treatment.
Niue’s success may have been further augmented by
the island’s natural climatic variability. Dry seasons in
Niue reduce the vector’s breeding sites, limiting trans-
mission to primarily the wet season rather than
year-round [15]. This, in addition to Niue’s consistent
vector control efforts (village inspections, actively
destroying man-made breeding sites) to concurrent con-
trol for dengue [15], could have contributed to the
elimination success seen in Niue. Further promotors of
Niue’s success include a well-conducted program,
strengthened by a constant program manager for over
ten years [15]. It is widely acknowledged that skilled
workforce migration and “brain drain” are common in
low-resource settings [26]. Stable leadership throughout
the national LF elimination program in Niue has, there-
fore, likely influenced its success. Similarly, Niue’s pro-
gram received strong political support from the Minister
of Health and sound technical advice from the WHO to
the program manager [15]. Political commitment and
will are essential to good health governance and expand-
ing responsibilities for health [26]. Lastly, unlike prior ef-
forts to eliminate LF in Niue, the MDA rounds in
PacELF consisted of a proven combination of DEC and
albendazole and continued for five consecutive rounds
until minimum thresholds were reached. Unlike in the
past, the MDA rounds were stopped only after assessing
that the PacELF elimination threshold level of 1% in all
ages was reached by testing the whole population. This
was also enhanced by the use of DOT in Niue. Wider pub-
lic–private partnerships between WHO, GlaxoSmithKline
(GSK), and the Japan International Cooperation Agency
(JICA) enabled mass donations of DEC (105,000 tablets),
albendazole (7400 tablets), and 6000 ICT testing kits to be
made available to Niue and contribute to the overarching
program’s success [1, 5].
Conclusion
At the commencement of PacELF in 1999, Niue’s na-
tional CFA prevalence in all ages was estimated at 3.1%.
After five rounds of MDA with combined DEC and
albendazole, this had reduced in all ages to 0.2% in 2004.
A post-MDA survey in 2009 showed a remaining
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antigen prevalence of 0.51% with no positive cases in
children aged six to seven years, suggesting transmission
has ceased and no recrudescence had occurred after the
stoppage of MDA. Results in Niue support the WHO
recommendation that five to six rounds of MDA with an
effective population coverage can successfully interrupt
LF transmission. In 2012, the Niue Health Department
compiled a dossier for its application for the validation
of the elimination of LF as a public health problem. The
dossier summarized surveillance and control activities
undertaken throughout the program. The dossier was
submitted to WHO in 2013 and was reviewed during
the meeting of the Western Pacific Regional Programme
Review Group (RPRG) in July 2014. An official acknow-
ledgement of the elimination of LF as a public health
problem was given to Niue by the WHO
Director-General and the WHO WPRO Regional Dir-
ector during the 67th session of the Regional Committee
held in Manila in October 2016. It should be noted that
LF is not eliminated globally. The status of LF elimin-
ation as a public health problem is also not irreversible;
therefore, Niue will need to remain vigilant in detecting
any recrudescence of the disease.
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